Literature DB >> 10733471

Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis.

S Bandoh1, J Fujita, Y Ohtsuki, Y Ueda, S Hojo, M Tokuda, H Dobashi, N Kurata, T Yoshinouchi, N Kohno, J Takahara.   

Abstract

OBJECTIVE: KL-6 is a mucin-like high molecular weight glycoprotein, which is strongly expressed on type II alveolar pneumocytes and bronchiolar epithelial cells. It has been demonstrated that the KL-6 antigen is a useful marker for estimating the activity of interstitial pneumonia. In this study, it is hypothesised that serum KL-6 is a useful marker to evaluate the activity of interstitial pneumonia associated with polymyositis/dermatomyositis (PM/DM).
METHODS: KL-6 was measured in sera in 16 patients diagnosed with PM/DM. Five had non-specific interstitial pneumonia (NSIP), three had diffuse alveolar damage (DAD), and eight had no pulmonary involvement, and 10 were normal non-smokers as a control group. The correlation was also evaluated between the KL-6 level and each clinical course in patients with pulmonary involvement associated with PM/DM. Immunohistochemical analysis using monoclonal anti-KL-6 antibody was also performed.
RESULTS: KL-6 concentrations in sera of patients with interstitial pneumonia associated with PM/DM were significantly high compared with those of PM/DM without interstitial pneumonia, and normal non-smokers. KL-6 concentrations in sera in patients with DAD significantly increased compared with those of other groups. KL-6 values in sera changed according to the progression or improvement of interstitial pneumonia. Immunohistochemical study using pulmonary tissues obtained from patients with DAD demonstrated that the hyaline membrane, proliferating type II pneumocytes, bronchial epithelial cells and some endothelial cells in pulmonary veins were stained by antihuman KL-6 antibody.
CONCLUSION: These data demonstrate that measurement of serum KL-6 was a useful marker to evaluate the activity of acute interstitial pneumonia associated with PM/DM.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10733471      PMCID: PMC1753113          DOI: 10.1136/ard.59.4.257

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  13 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer.

Authors:  N Kohno; H Hamada; S Fujioka; K Hiwada; M Yamakido; M Akiyama
Journal:  Chest       Date:  1992-07       Impact factor: 9.410

3.  Interstitial pneumonitis in dermatomyositis.

Authors:  E S MILLS; W H MATHEWS
Journal:  J Am Med Assoc       Date:  1956-04-28

4.  New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6.

Authors:  N Kohno; S Kyoizumi; Y Awaya; H Fukuhara; M Yamakido; M Akiyama
Journal:  Chest       Date:  1989-07       Impact factor: 9.410

5.  Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings.

Authors:  H D Tazelaar; R W Viggiano; J Pickersgill; T V Colby
Journal:  Am Rev Respir Dis       Date:  1990-03

6.  A novel method for screening monoclonal antibodies reacting with antigenic determinants on soluble antigens; a reversed indirect-enzyme linked immunosorbent assay (RI-ELISA).

Authors:  N Kohno; M Akiyama; S Kyoizumi; M Tanabe; T Oyama; M Yamakido
Journal:  Hiroshima J Med Sci       Date:  1987-12

7.  KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease.

Authors:  N Kohno; Y Awaya; T Oyama; M Yamakido; M Akiyama; Y Inoue; A Yokoyama; H Hamada; S Fujioka; K Hiwada
Journal:  Am Rev Respir Dis       Date:  1993-09

8.  Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma.

Authors:  N Kohno; M Akiyama; S Kyoizumi; M Hakoda; K Kobuke; M Yamakido
Journal:  Jpn J Clin Oncol       Date:  1988-09       Impact factor: 3.019

9.  Acute interstitial pneumonia. A clinicopathologic, ultrastructural, and cell kinetic study.

Authors:  A L Katzenstein; J L Myers; M T Mazur
Journal:  Am J Surg Pathol       Date:  1986-04       Impact factor: 6.394

10.  KL-6: a serum marker for interstitial pneumonia.

Authors:  J Kobayashi; S Kitamura
Journal:  Chest       Date:  1995-08       Impact factor: 9.410

View more
  23 in total

1.  Non-specific interstitial pneumonia; as the first clinical presentation of various collagen vascular disorders.

Authors:  Toshio Sato; Jiro Fujita; Ichiro Yamadori; Yuji Ohtsuki; Takeo Yoshinouchi; Shuji Bandoh; Michiaki Tokuda; Toshihiko Ishida
Journal:  Rheumatol Int       Date:  2005-11-08       Impact factor: 2.631

2.  Successful treatment of rapidly progressive interstitial pneumonia with autologous peripheral blood stem cell transplantation in a patient with dermatomyositis.

Authors:  Kensuke Oryoji; Daisuke Himeji; Kouji Nagafuji; Takahiko Horiuchi; Hiroshi Tsukamoto; Hisashi Gondo; Mine Harada
Journal:  Clin Rheumatol       Date:  2005-05-18       Impact factor: 2.980

Review 3.  Update on outcome assessment in myositis.

Authors:  Lisa G Rider; Rohit Aggarwal; Pedro M Machado; Jean-Yves Hogrel; Ann M Reed; Lisa Christopher-Stine; Nicolino Ruperto
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

4.  Utilize lung ultrasound B-lines and KL-6 to monitor anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis-associated interstitial lung disease: a case report and literature review.

Authors:  Yukai Wang; Shaoqi Chen; Zhangzhang Lin; Jianqun Lin; Xuezhen Xie; Qisheng Lin; Guangzhou Du; Xiufeng Huang; Marco Matucci-Cerinic; Daniel E Furst
Journal:  Clin Rheumatol       Date:  2019-02-11       Impact factor: 2.980

Review 5.  Peripheral blood biomarkers in idiopathic pulmonary fibrosis.

Authors:  Rekha Vij; Imre Noth
Journal:  Transl Res       Date:  2012-02-02       Impact factor: 7.012

Review 6.  Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis.

Authors:  Wanlong Wu; Li Guo; Yakai Fu; Kaiwen Wang; Danting Zhang; Wenwen Xu; Zhiwei Chen; Shuang Ye
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-06       Impact factor: 8.667

Review 7.  Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

Authors:  Tsuneyo Mimori; Ran Nakashima; Yuji Hosono
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

8.  Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis.

Authors:  Yun Peng; Suhan Zhang; Yi Zhao; Yi Liu; Bing Yan
Journal:  Clin Rheumatol       Date:  2017-08-25       Impact factor: 2.980

Review 9.  Amiodarone: review of pulmonary effects and toxicity.

Authors:  Spyros A Papiris; Christina Triantafillidou; Likurgos Kolilekas; Despoina Markoulaki; Effrosyni D Manali
Journal:  Drug Saf       Date:  2010-07-01       Impact factor: 5.606

Review 10.  Pulmonary complications of inflammatory myopathy.

Authors:  Dana P Ascherman
Journal:  Curr Rheumatol Rep       Date:  2002-10       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.